DPTX-3496 / Dewpoint Therap - LARVOL DELTA

Dewpoint Therapeutics Announces DPTX3496 as a Development Candidate for the Treatment of Colorectal, Breast, and Lung Cancers (GlobeNewswire) - "Dewpoint Therapeutics Inc...announced today the nomination of a second development candidate (DC), DPTX3496....Based on the preclinical data package, IND-enabling studies have commenced for DPTX3496 with an IND filing planned for the second half of this year....DPTX3496 has demonstrated tumor regression and stasis in a broad panel of Wnt-driven tumors, including patient-derived xenograft (PDX) mouse models of CRC, TNBC, and NSCLC, along with good tolerability and minimal body weight loss....DPTX3496 shows down-regulation of beta catenin-driven gene transcription and Wnt pathway activity in vivo, and plasma protein profiling demonstrates modulation of systemic disease-associated beta catenin target genes."

IND • Preclinical • Colorectal Cancer • Non Small Cell Lung Cancer • Triple Negative Breast Cancer

Dewpoint Therapeutics and ConcertAI Announce the First Phase of their Translational Oncology Partnership (GlobeNewswire) - "Dewpoint Therapeutics and ConcertAI announced the first phase of their Translational Oncology partnership, aligned around Dewpoint’s latest drug candidate, DPTX3186...The first phase of the partnership will support DPTX3186 development by optimizing patient stratification through the synergy between Dewpoint’s AI/ML-powered discovery and development platform, and ConcertAI’s clinico-genomic data sets and the CARAai platform. Future phases of the partnership are anticipated to similarly support other candidates in Dewpoint’s oncology pipeline, including a second beta catenin c-mod with indications for other Wnt-driven tumor types, set for investigational new drug (IND) in 2025, and a c-mod for MYC, another ‘undruggable’ oncogene, set for IND in 2026."

Commercial • IND • Oncology